RT Journal Article
SR Electronic
T1 Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.21.20026161
DO 10.1101/2020.02.21.20026161
A1 Vergnano, Marta
A1 Grys, Katarzyna
A1 Benzian-Olsson, Natashia
A1 Mahil, Satveer K
A1 Chaloner, Charlotte
A1 Barbosa, Ines A
A1 August, Suzannah
A1 Burden, A David
A1 Choon, Siew-Eng
A1 Cooper, Hywel
A1 Reynolds, Nick
A1 Wahie, Shyamal
A1 Warren, Richard B
A1 Wright, Andrew
A1 ,
A1 Huffmeier, Ulrike
A1 Baum, Patrick
A1 Visvanathan, Sudha
A1 Barker, Jonathan
A1 Smith, Catherine
A1 Capon, Francesca
YR 2020
UL http://medrxiv.org/content/early/2020/02/23/2020.02.21.20026161.abstract
AB The identification of disease alleles underlying human autoinflammatory diseases can provide important insights into the mechanisms that maintain neutrophil homeostasis. Here, we focused on generalized pustular psoriasis (GPP), a potentially life-threatening disorder presenting with cutaneous and systemic neutrophilia. Following the whole exome sequencing of 19 unrelated cases, we identified one affected individual harbouring a homozygous splice-site mutation (c.2031-2A>C) in MPO. The same homozygous change was subsequently identified in a further subject suffering from acral pustular psoriasis, a disease phenotypically related to GPP.MPO encodes myeloperoxidase, an essential component of neutrophil azurophil granules. Of interest, the c.2031-2A>C allele was previously described as a genetic determinant of myeloperoxidase deficiency (MPOD), a condition which can causes recurrent infections. Here, a systematic literature review identified four individuals suffering from MPOD and pustular skin disease, further strengthening the link between MPO and pustular inflammation.A subsequent analysis of the UK Biobank cohort demonstrated that the c.2031-2A>C allele was associated with increased neutrophil abundance in the general population (P=5.1×10−6). The same applied to three further MPOD mutations for which genotype data was available, with two alleles generating p-values <10−10. Finally, treatment of healthy neutrophils with an MPO inhibitor reduced cell apoptosis, highlighting a mechanism whereby MPO mutations affect granulocyte numbers.These findings identify MPO mutations as genetic determinants of pustular skin disease and neutrophil abundance. Given the recent interest in the development of MPO antagonists for the treatment of neurodegenerative disease, our results also suggest that the pro-inflammatory effects of these agents should be closely monitored.Competing Interest StatementFC and JNB have received funding from Boehringer-Ingelheim. PB and SV are Boehringer-Ingelheim employees.Funding StatementWe acknowledge support from the Department of Health via a Biomedical Research Centre award to Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust (guysbrc-2012-1). The APRICOT trial is funded by the Efficacy and Mechanism Evaluation Programme (grant EME 13/50/17). UH is funded by the DFG (CRC1181, Project A05). MV is supported by a Medical Research Council (MRC) PhD studentship, NBO by a NIHR pre-doctoral fellowship (NIHR300473) and SKM by an MRC Clinical Academic Research Partnership award (MR/T02383X/1). RBW is supported by the Manchester NIHR Biomedical Research Centre.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is included in the manuscript